Small 2024 research project conducted through Maastricht University within the context of the European AD-RIDDLE initiative.

The project focused on Alzheimer’s disease blood-based biomarkers, particularly amyloid-β measures such as the Aβ42/40 ratio, supporting research into scalable and minimally invasive approaches for earlier detection of Alzheimer’s disease pathology.

AD-RIDDLE develops and validates tools for risk assessment, early diagnosis, prevention, and treatment of Alzheimer’s disease across real-world clinical settings.

Project website: https://ad-riddle.org/